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Abstract 
Background: Despite numerous studies on cardioprotective effects of omega‑3 polyunsaturated fatty acids (n‑3 
PUFAs), there is limited evidence for n‑3 PUFA‑mediated effects, especially at its higher dose, on cardiovascular risk in 
patients with type 2 diabetes (DM2) and established atherosclerosis.
Purpose: To investigate the effect of daily treatment with a higher dose (2 g) of n‑3 PUFAs on platelet function, 
coagulation parameters, fibrin clot properties, markers of systemic inflammation and metabolic status, in patients 
with atherosclerotic vascular disease and DM2 who receive optimal medical therapy.
Methods: We conducted a prospective, double‑blind, placebo‑controlled, randomized, double‑center study, in 
which thrombin generation (plasma thrombogenic potential from automated thrombogram), fibrin clot properties 
(plasma fibrin clot permeability; lysis time), platelet aggregation (light transmission aggregometry with adenosine 
diphosphate and arachidonic acid used as agonists), HbA1c, insulin level, lipid profiles, leptin and adiponectin levels, 
as well as markers of systemic inflammation (i.e., hsCRP, IL‑6, TNF‑α, ICAM‑1, VCAM‑1, and myeloperoxidase) were 
determined at baseline and at 3 months after treatment with 2 g/day of n‑3 PUFAs (n = 36) or placebo (n = 38). 
Moreover, we assessed serum fatty acids of the phospholipid fraction by gas chromatography both at baseline and at 
the end of the study.
Results: Majority of patients were treated with optimal medical therapy and achieved recommended treatment 
targets. Despite higher serum levels of eicosapentaenoic acid (EPA) (by 204%; p < 0.001) and docosahexaenoic acid 
(DHA) (by 62%; p < 0.0001) in n‑3 PUFA group at the end of treatment no changes in platelet aggregation, thrombin 
generation, fibrin clot properties or markers of systemic inflammation were observed. No intergroup differences in the 
insulin, HbA1c and lipid levels were found at the end of the study. There was no change in adiponectin and leptin in 
interventional group, however leptin increased in control group (p = 0.01), therefore after study period leptin levels 
were lower in the interventional group (p = 0.01). Additionally, resolvin D1 did not differ between interventional and 
control group.
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Background
Numerous studies have provided evidence for pleiotropic 
and cardioprotective effects of omega-3 polyunsaturated 
fatty acids (n-3 PUFAs). Currently, with advances in 
pharmacological and interventional cardiovascular (CV) 
therapy, the results of major randomized controlled tri-
als (RCTs) have challenged the beneficial effect of n-3 
PUFAs on CV risk [1, 2]. On the other hand, a recently 
published RCT, with a higher dose of n-3 PUFAs, has 
shown their favorable effects in patients after acute myo-
cardial infarction [3]. However, no RCTs so far have 
assessed the effects of a higher dose of n-3 PUFAs on CV 
risk in patients with type 2 diabetes (DM2) and estab-
lished atherosclerosis.
Diabetes is a well-known prothrombotic and hypofi-
brinolytic state due to increased platelet reactivity 
and enhanced secondary hemostasis [4]. Moreover, in 
patients with DM2 and CV diseases (CVDs), thrombin 
generation is even more increased than in patients with 
DM2 without CVDs [5]. Despite advances in modern 
therapy, patients with diabetes continue to have worse 
prognosis, and enhanced thrombotic environment has 
been shown to play a key role in unfavorable clinical out-
comes [4]. Moreover, enhanced coagulability has been 
found to be associated with both microvascular [6] and 
macrovascular complications [7] in DM2. Although one 
RCT has suggested no benefits of low-dose n-3 PUFAs in 
dysglycemia [2], there have been no trials elucidating the 
mechanisms by which the effectiveness of n-3 PUFAs is 
reduced in DM2. It is possible that the negative conse-
quences of long-standing, suboptimally controlled DM2, 
the so called “metabolic memory”, may limit the benefits 
not only of further intensive glucose control therapy but 
also of n-3 PUFA supplementation in diabetic patients. 
The high effectiveness of modern optimal medical ther-
apy (OMT) may also limit the effects of n-3 PUFAs. 
Moreover, there is limited evidence from RCTs on the 
impact of n-3 PUFAs on platelets, coagulation, fibrin clot 
properties, as well as on metabolic balance in high-risk 
patients with both atherosclerosis and DM2, especially 
when added to OMT including potent pharmaceuticals 
[such as statins at high doses and angiotensin-convert-
ing-enzyme inhibitors (ACEIs)] and optimal glucose con-
trol. The pathogenesis of DM2 is strongly associated with 
insulin resistance (IR) as one of the major complications 
of obesity. The adipokine profile deteriorates in obe-
sity and obesity-related conditions, including DM2 [8]. 
A few adipokines have been suggested to participate in 
the development of systemic low-grade inflammation, IR 
and metabolic syndrome [9]. Moreover, disturbances in 
adipokine profiles have also been associated with inade-
quate lipid control [10]. Since dysregulation of adipokine 
secretion plays an important role in the pathogenesis of 
DM2 and its macrovascular complications, the amelio-
ration of adipokine pattern may improve prognosis in 
patients with DM2. It has been shown that n-3 PUFAs 
may improve insulin sensitivity in animal model [11] 
and modulate adipokine gene expression in animals and 
humans [12]. However, data supporting the impact of n-3 
PUFAs on adipokine profile, systemic inflammation, glu-
cose homeostasis, insulin sensitivity, and lipid metabo-
lism in DM2 are still limited and inconsistent.
The main purpose of the current study was to investi-
gate the effect of daily treatment with a higher dose (2 g) 
of n-3 PUFAs on platelet function, coagulation param-
eters, clot properties, as well as markers of systemic 
inflammation and metabolic status (i.e., HbA1c, insulin 
level, lipid profiles and leptin and adiponectin levels), in 
patients with atherosclerotic vascular disease and DM2 
who receive OMT.
Methods
Patients
During the period between 04.2014 and 03.2015 we eval-
uated 126 consecutive patients from the outpatient car-
diology department with DM2 and a history of coronary 
artery disease (CAD) or peripheral artery disease, who 
fulfilled the study criteria. The exclusion criteria were 
as follows: pregnancy, type 1 diabetes, poorly controlled 
DM2 [hemoglobin A1c (HbA1c) >9%], acute coronary 
syndrome (within the previous 3  months), percutane-
ous coronary intervention or coronary artery bypass 
grafting (within the previous month), percutaneous or 
surgical revascularization (within the previous month), 
acute infection, hypertriglyceridemia, n-3 PUFA treat-
ment, active bleeding, any known coagulation or bleed-
ing disorder, oral anticoagulant therapy, platelet count 
<100  ×  109/L, serum creatinine levels >177  μmol/L 
Conclusions: In conclusion, our study demonstrated that in patients with long‑standing, well‑controlled DM2 and 
atherosclerotic disease the treatment with a high dose of n‑3 PUFAs (namely, 1 g/day of EPA and 1 g/day of DHA for 
3 months) does not improve coagulation, metabolic, and inflammatory status when measured with the specified 
tests.
The study was registered in ClinicalTrials.gov; identifier: NCT02178501. Registration date: April 12, 2014
Keywords: Cardiovascular disease, Atherosclerosis, Diabetes type 2, Omega‑3 polyunsaturated fatty acids
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(2 mg/dL), liver injury [alanine transaminase (ALT) levels 
>1.5 times above the upper limit of the reference range], 
chronic therapy with nonsteroidal anti-inflammatory 
drugs, except for acetylsalicylic acid or steroids, alco-
hol or drug abuse, known sensitivity or allergy to fish or 
PUFA supplements, history of malignancy (unless disease 
free for >10 years, or non-melanoma skin carcinoma), life 
expectancy <12  months due to concomitant diseases, 
abnormality of laboratory or imaging tests that would 
hamper the interpretation of results, and any threatening 
condition during the study (Fig. 1).
Study design
We conducted a prospective, double-blind, placebo-
controlled, randomized, double-center study. In the first 
month, eligible patients who consented to participate 
in the study underwent optimization of DM2 and CVD 
therapy in accordance with the current guidelines. Then, 
patients were randomized at a ratio of 1:1, using com-
puterized random-number generation by an independ-
ent investigator on a double-blind basis to either a n-3 
PUFA (OMT plus n-3 PUFA supplementation) or pla-
cebo group (OMT). n-3 PUFAs were administered with 
the Smartfish drink (Smartfish, Oslo, Norway): eicosap-
entaenoic acid (EPA), 1 g/day, and docosahexaenoic acid 
(DHA), 1 g/day (stabilized against oxidation by botanical 
additives: pomegranate, chokeberry, and transresvera-
trol). The placebo group received the same drink with-
out n-3 PUFAs. Compliance was assessed based on the 
number of packages of study substance returned at each 
visit in both groups as well as on plasma concentrations 
of EPA and DHA. Patients were encouraged to increase 
their consumption of oily fish and comply with the diet 
recommended by the European Society of Cardiology. 
The study complied with the principles of the Good 
Clinical Practice International Conference on Harmo-
nization rules and was approved by the University Eth-
ics Committee. Each study participant provided written 
informed consent.
The study was registered in ClinicalTrials.gov; identi-
fier: NCT02178501. Registration date: April 12, 2014.
Blood sampling and laboratory measurements
Fasting blood samples were obtained between 8 and 
10 a.m. after overnight fast. The samples were pro-
cessed 30–60  min after blood collection and stored at 
−70  °C until further analysis. Blood for platelet aggre-
gation was not frozen prior to analysis. Blood was taken 
from the antecubital vein, with minimal stasis at 2 time 
points: at baseline (i.e., after 1 month of OMT) and after 
3  months of n-3 PUFA or placebo supplementation. 
Routine blood tests, including the measurement of com-
plete blood count, lipid profile, and the levels of aspar-
tate aminotransferase (AST), ALT, and serum creatinine, 
were done by automated laboratory techniques. HbA1c 
levels were measured using a turbidimetric inhibition 
immunoassay.
Platelet aggregation was assessed with the use of 
light transmission aggregometry. Platelets were stimu-
lated with 10  µmol/L of adenosine diphosphate (ADP) 
and 5  mmol/L of arachidonic acid. Then, aggregation 
was measured with the use of a 2-channel Chronolog 
Aggregometer (Chrono-Log 490; Chrono-Log Corp., 
Haverton, Pennsylvania) and expressed as the maximum 
change in light transmission from baseline, in percent-
ages, with platelet-poor plasma as a reference.
Plasma thrombogenic potential was assessed on the 
basis of a thrombogram, analyzed with the use of the 
CAT (Thrombinoscope BV, Maastricht, the Nether-
lands), according to the protocol of the manufacturer in a 
96-well plate fluorometer (Ascent Reader, Thermolabsys-
tems OY, Helsinki, Finland) equipped with the 390/460 
filter set at 37 °C.
To assess plasma clot lysis, plasmin-mediated fibrinoly-
sis was evaluated in the presence of recombinant tissue 
plasminogen activator (Boehringer Ingelheim, Ingelheim, 
Germany). Lysis time was chosen as a marker of the clot 
susceptibility to fibrinolysis. It was defined as the time 
needed for a 50% reduction of fibrin clot absorbance.
To assess fibrin clot permeability, calcium chloride 
(20  mmol/L) and human thrombin (1  U/mL) were 
added to 120 μL of citrated plasma. After incubation for 
120 min, tubes with the clots were connected to a con-
tainer with a buffer (10  mmol/L: 0.05  mol/L Tris–HCl; 
100 mmol/L: 0.15 mol/L NaCl, pH 7.5). Its volume flow-
ing through the gels was measured within 60 min. Then, a 
permeation coefficient was calculated, indicating the size 
of fibrin clot pores.
126 pts with DM2 assessed for eligibility; 50 pts were not eligible: 
43: exclusion criteria,7: refused informed consent
76 patients randomized; 1:1 ratio to n-3 PUFAs supplementation of 
1000 mg EPA and 1000 mg DHA or placebo
38 pts interventional group, 
OMT+ n-3 PUFAs; 2 pts were 
excluded due to noncompliance 
to treatment
Study group: 36 pts n-3 PUFAs 
group
38 pts placebo group, OMT
Laboratory tests were performed before and after 3 months of 
n-3 PUFAs or placebo supplementation 
Fig. 1 Study flow chart. n-3 PUFAs omega‑3 polyunsaturated fatty 
acids, EPA eicosapentaenoic acid, DHA docosahexaenoic acid, pts 
patients, OMT optimal medical therapy
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Latex nephelometry was used to measure fibrinogen 
and high-sensitivity C-reactive protein levels (hsCRP; 
Dade Behring, Marburg, Germany). The levels of 
interleukin 6 (IL-6), tumor necrosis factor α (TNF-α), 
intercellular adhesion molecule 1 (ICAM-1), vascular 
adhesion molecule 1 (VCAM-1), and myeloperoxidase 
were measured by an enzyme-linked immunosorb-
ent assay (R&D Systems, USA). An immunoenzymatic 
assay was used to determine prothrombin fragment 
1.2 (F1.2) (Siemens, Marburg, Germany). Plasma pro-
thrombin levels were determined by 1-stage clotting 
assays using factor-deficient plasma (Dade Behring, 
Liederbach, Germany). Resolvin D1 (RvD1) levels were 
measured by the RvD1 EIA Kit (Cayman Chemical 
Company, USA).
Serum leptin and adiponectin levels were determined 
by radioimmunoassay kits (DIAsource, Belgium). Insulin 
levels were measured using the chemiluminescent immu-
noassay method (Advia Centaur, Siemens Healthcare, 
USA) with intra- and interassay variabilities ranging from 
3.2 to 4.6% and from 2.6 to 5.9%, respectively. The meas-
urement of serum peptide C levels was performed using 
radioimmunoassay kits (DIAsource, Belgium).
The assessment of body composition was performed 
using a bioelectrical impedance analysis.
n‑3 PUFA measurement
The analytical procedure consisted of a few separate 
steps: (1) extraction of serum total lipids; (2) separation 
of the lipid fraction on Sep-PakNH2 columns (Waters, 
Milford, Mass., USA); (3) methylation and separation 
of the fatty acid from the phospholipid fraction by gas 
chromatography (Agilent Technologies 6890N Net-
work GC Systems, Wilmington, De., USA) equipped 
with an Agilent J&W HP-88 capillary column (100  m, 
0.250  mm, 0.20  µm) (Agilent Technologies, USA). 
1,2-dipentadecanoil-sn-glicero-3-phosphocholine 
(Sigma-Aldrich, Steinheim, Germany) was used as an 
internal standard. The method was calibrated using 
the calibration mixture (all fatty acids: Sigma-Aldrich, 
Steinheim, Germany). The plasma levels of saturated 
acids (lauric, C12; myristic, C14; palmitic, C16; stearic, 
C18; lignoceric, C24) and unsaturated acids (n-7 [pal-
mitoleic, C16:1], n-9 [oleic, C18:1], n-3 [alfa-linolenic, 
C18:3; EPA, C20:5; DHA, C22:6], and n-6 [linoleic, 
C18:2; eicosadienoic C20:2; arachidonic -AA, C20:4] of 
the phospholipid fraction were quantitatively measured 
by gas chromatography. The concentration of serum 
fatty acids of the phospholipid fraction was expressed 
in µmol/L.
All laboratory tests were performed by investigators 
blinded to the sample origin.
Statistical analysis
Categorical variables were presented as numbers and 
percentages. Continuous variables were expressed as 
mean  ±  standard deviation (SD) or median and inter-
quartile range (IQR). Differences between the groups 
were compared using the Student’s or the Welch’s t test 
depending on the equality of variances for normally dis-
tributed variables. The Mann–Whitney U test was used 
for nonnormally distributed continuous variables. Nor-
mality was assessed by the Shapiro–Wilk test. The equal-
ity of variances was assessed using the Levene’s test. 
Categorical variables were compared by the Fisher’s exact 
test for 2 × 2 tables or by the Pearson’s Chi squared test 
for other tables. For pairwise comparisons, the paired t 
test was used if the difference between variables was nor-
mally distributed. The Wilcoxon signed-rank test was 
used for nonnormally distributed differences. The Pear-
son correlation coefficient was computed to measure the 
linear dependence between two normally distributed 
variables. The Spearman’s rank correlation coefficient 
was calculated to measure monotonic trend between two 
variables if the distribution of the variables was nonnor-
mal. Two-sided p values <0.05 were considered statisti-
cally significant. All calculations were done with JMP®, 
Version 9.0.0 SAS Institute Inc., Cary, NC, 1989–2007.
The sample size was calculated based on our previous 
studies [13, 14]. The primary endpoint of this study was 
the change in the levels of markers of thrombin genera-
tion, fibrin clot properties, and platelet aggregation after 
3  months of treatment with n-3 PUFAs. The secondary 
endpoint was the improvement in the markers of systemic 
inflammation and metabolic status. We hypothesized 
that the addition of n-3 PUFAs to OMT compared with 
placebo would result in an absolute 14% reduction of the 
maximum thrombin concentration with an SD of the dif-
ferences between the two groups of 13%. We speculated 
that the addition of n-3 PUFAs to OMT compared with 
placebo would result in an absolute 15% increase of per-
meation coefficient with an SD of the differences between 
the two groups of 15%. We also hypothesized that the 
addition of n-3 PUFAs to OMT compared with placebo 
would result in an absolute 13% reduction of the maxi-
mum platelet aggregation induced by 5  µmol/L of ADP 
with an SD of the differences between the two groups of 
13%. Choosing a power of 90% and a 2-sided alpha level of 
0.05, at least 23 patients in each group were required.
Results
Baseline characteristics
A total of 74 consecutive patients (49 men and 25 women; 
mean age, 65.6 ± 6.8 years) were analyzed (Fig. 1). Base-
line demographic data, clinical characteristics, laboratory 
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results, and the use of concomitant medications in rand-
omized patients are shown in Table 1. There were no dif-
ferences at baseline between the groups, except for lower 
adiponectin (p = 0.01) and higher triglyceride (TG) levels 
(p = 0.01) in the n-3 PUFA group (Tables 1, 2, 3; Addi-
tional file 1: Table S1).  
Coagulation parameters
At baseline there were no significant intergroup differ-
ences in the markers of thrombin generation and fibrin 
clot properties. After 3 months of n-3 PUFA treatment, 
no intergroup differences were found in fibrin clot prop-
erties and most markers of thrombin generation, except 
for F1.2. A within-group analysis showed that there was 
a trend towards an increase in F1.2 levels in the placebo 
group (p  =  0.05) during the study period, while this 
parameter remained unaltered in the n-3 PUFA group 
(p = 0.53). As a result, F1.2 levels were lower in the n-3 
PUFA group (p =  0.04) at the end of the study, but the 
differences were of borderline significance (Table  2; 
Fig. 2).
Platelet function
Platelet aggregation measured by specified test described 
above, did not differ between the groups at baseline and 
did not change after 3  months of treatment, with no 
intergroup posttreatment differences (Table 2; Fig. 2).
Glucose and metabolic parameters
During the n-3 PUFA treatment, no significant changes 
in the levels of HbA1c, insulin, or peptide C were 
observed in either interventional or placebo group; there-
fore, no intergroup differences were found at the end of 
the study (Table 3).
No significant intergroup differences in the levels of 
TG, total cholesterol (TC), low-density lipoprotein cho-
lesterol (LDL-C), and high-density lipoprotein choles-
terol (HDL-C) were found after the n-3 PUFA treatment. 
However, there was a trend towards a decrease of TG 
levels in the interventional group (p = 0.125) and a trend 
towards an increase of TG levels in the placebo group 
(p = 0.09) (Table 3).
Both, before and after the treatment with n-3 PUFAs, 
adiponectin levels were higher in the interventional 
group than in placebo group (p  =  0.01 and p  =  0.03, 
respectively). There was no change in adiponectin levels 
during the study period in either of the groups (Table 3).
At baseline, there was a trend towards higher leptin 
levels in the placebo group (p = 0.09). Moreover, leptin 
levels increased in this group during the study period 
(p =  0.01). Therefore, after 3  months of treatment with 
n-3 PUFAs, leptin levels were lower in the interventional 
group (p = 0.01) (Table 3).
Markers of inflammation and resolvin D1
After 3 months of treatment with n-3 PUFAs, the markers 
of inflammation (hsCRP, IL-6, TNF-α, ICAM-1, VCAM-
1, and myeloperoxidase) did not differ between the 
Table 1 Baseline characteristics of  the study population 
(n = 74)
Data shown as number (percentage) for categorical variables and mean 
(±standard deviation) or median (IQR) for continuous variables
CAD coronary artery disease, PAD peripheral artery disease, MI myocardial 
infarction, PCI percutaneous coronary intervention, eGFR (MDRD) estimated 
glomerular filtration rate calculated by the abbreviated MDRD equation, ACEI 
angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker, 
ASA acetylsalicylic acid, PPI proton pump inhibitors, AA aldosterone antagonist
Variables Placebo
N = 38
n‑3 PUFAs
N = 36
Age (years) 66.7 (±6.8) 64.4 (±6.7)
Female sex, n (%) 12 (31.6) 14 (38.9)
Hypertension, n (%) 36 (93.7) 36 (100)
Hyperlipidemia, n (%) 22 (57.9) 28 (77.8)
Metabolic syndrome, n (%) 38 (100) 36 (100)
Obesity, n (%) 25 (65.8) 23 (63.9)
Waist circumference (cm) 107 (98; 113) 106 (99; 112)
Body mass index (kg/m2) 31.1 (28.1; 32.7) 30.9 (27.9; 34.7)
Body fat (%) 30.4 (27.4; 35.8) 34.0 (31.0; 43.0)
Visceral fat (%) 15.74 (±4.9) 16.25 (±4.5)
Total body water (%) 47.9 (43.9; 49.8) 47.5 (44.2; 49.2)
Muscle mass (kg) 53.5 (±11.5) 56.85 (±9.2)
DM2 duration (years) 10 (6; 15) 10 (6.5; 15)
CAD, n (%) 38 (100) 36 (100)
PAD, n (%) 14 (38.9) 12 (31.3)
Previous MI, n (%) 16 (42.1) 12 (33.3)
Previous PCI, n (%) 25 (65.8) 22 (61.1)
Creatinine (μmol/L) 84 (66; 94) 86.5 (74; 100)
eGFR (MDRD) (mL/min/1.73 m2) 78.6 (70; 90) 78 (69; 89)
Treatment, n (%)
 Beta blocker 31 (81.6) 30 (83.3)
 ACEI or ARB 33 (86.8) 34 (94.4)
 Long acting nitrate 5 (13.2) 6 (16.7)
 Calcium antagonist 13 (34.2) 19 (52.8)
 Statin 33 (86.8) 35 (97.2)
 Fibrate 0 1 (2.78)
 ASA 38 (100) 36 (100)
 Clopidogrel 19 (50) 14 (38.9)
 Metformin 24 (63.2) 25 (69.4)
 Sulfonylurea 14 (36.8) 17 (47.2)
 Acarbose 1 (2.6) 2 (5.6)
 DPP‑IV 1 (2.6) 0
 Insulin 16 (42.1) 16 (44.4)
 PPI 10 (26.3) 12 (33.3)
 Loop diuretic 6 (15.8) 3 (8.3)
 Diuretic 11 (28.9) 11 (30.6)
 AA 6 (15.8) 3 (8.3)
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interventional and placebo groups. Despite an increase of 
both EPA and DHA levels in the n-3 PUFA group, rvD1 
levels did not differ between the groups (Table 3).
Fatty acids
After 3 months of treatment with n-3 PUFAs, DHA levels 
increased by 154.5 µmol/L (54.5%) in the interventional 
group and were higher by 61.6% in the n-3 PUFA group 
compared with placebo (p < 0.0001). EPA levels increased 
by 101.5  µmol/L (161.2%) in the n-3 PUFA group and 
were higher by 204.3% in the interventional group com-
pared with the placebo group (p < 0.0001). At the end of 
the study, the n-6:n-3 ratio was lower by 57.3% in the n-3 
PUFA group compared with placebo (p < 0.0001) (Addi-
tional file 1: Table S1, Additional file 2: Figure S1).
Adverse events
The observed adverse events were rated as mild and did 
not require medical intervention. Their frequency was 
Table 2 Effects of 3 months of 2-g n-3 PUFA supplementa-
tion on clot properties, coagulation parameters and plate-
let function
Data shown as number (percentage) for categorical variables and mean 
(±standard deviation) or median (IQR) for continuous variables
Ks permeation coefficient, t50% clot lysis time, Lag time lag time peak height, 
ETP endogenous thrombin potential (an area under the thrombin concentration 
versus the time curve), Peak maximal thrombin concentration, tt peak time 
do peak, F1.2 prothrombin fragments, PR ADP platelet aggregation 10 µmol/L 
adenosine diphosphate, PR AA platelet aggregation 5 mmol/L arachidonic acid
* p = 0.05 within the placebo group; ** p = 0.53 within the n-3 PUFA group
Variable Placebo n‑3 PUFAs p value
Fibrinogen (g/L)
 Before 2.70 (2.60; 2.95) 2.74 (2.60; 2.97) 0.70
 After 2.73 (2.58; 2.85) 2.72 (2.57; 2.87) 0.91
t50% (min)
 Before 13.14 (±2.77) 13.55 (±3.07) 0.55
 After 12.58 (±2.70) 13.76 (±2.59) 0.07
Lag time (min)
 Before 2.94 (2.52; 3.27) 2.61 (2.33; 3.21) 0.35
 After 2.94 (2.60; 3.28) 2.84 (2.56; 3.17) 0.75
Peak (nM)
 Before 264.54 (220.08; 314.92) 247.05 (211.89; 287.34) 0.27
 After 249.59 (190.94; 336.52) 243.83 (207.82; 293.65) 0.98
tt peak (min)
 Before 5.87 (±0.92) 5.94 (±1.03) 0.76
 After 5.62 (5.00; 6.96) 5.98 (4.96; 6.89) 0.89
F1.2 (pg/mL)
 Before 41.40 (28.80;48.10) 34.70 (26.95; 46.85) 0.56
 After 43.70 (33.90; 49.30)* 37.70 (27.40; 41.55)** 0.04
PR ADP (%)
 Before 57.96 (±14.02) 54.44 (±14.27) 0.36
 After 60.56 (±15.12) 58.19 (±12.52) 0.54
Table 3 Effects of  3  months of  2-g n-3 PUFAs supple-
mentation on  metabolic status, inflammatory markers 
and resolvin D1
Variables Placebo
N = 38
n‑3 PUFAs
N = 36
p value
HbA1c (%)
 Before 7.00 (6.50; 7.50) 7.00 (6.70; 7.48) 0.45
 After 6.80 (6.50; 7.35) 7.10 (6.90; 7.75) 0.06
Insulin (mU/mL)
 Before 22.30 (16.20; 33.63) 20.85 (12.85; 34.80) 0.59
 After 16.80 (12.83; 32.23) 22.35 (13.33; 39.58) 0.72
Peptide C (pmol/mL)
 Before 2.99 (2.10; 4.07) 3.27 (2.70; 4.11) 0.43
 After 2.87 (1.97; 4.03) 3.30 (2.41; 4.64) 0.15
TC (mmol/L)
 Before 3.53 (3.16; 4.21) 3.80 (3.25; 4.63) 0.50
 After 3.78 (3.25; 4.45) 3.50 (3.11; 4.35) 0.53
LDL‑C (mmol/L)
 Before 1.84 (1.47; 2.48) 2.07 (1.62; 2.83) 0.51
 After 2.07 (1.71; 2.54) 1.81 (1.44; 2.59) 0.24
HDL‑C (mmol/L)
 Before 1.23 (1.04; 1.56) 1.22 (0.90; 1.39) 0.45
 After 1.24 (0.99; 1.47) 1.19 (0.91; 1.56) 0.76
TG (mmol/L)
 Before 1.30 (0.95; 1.62) 1.79 (1.8; 2.41) 0.01
 After 1.41 (1.13; 1.72) 1.48 (0.91; 2.08) 0.69
Leptin (ng/mL)
 Before 5.66 (2.54; 9.14) 3.26 (1.21; 8.09) 0.09
 After 6.14 (3.02; 12.19)* 3.45 (1.35; 8.18) 0.01
Adiponectin (ng/mL)
 Before 4.03 (3.21; 6.35) 3.52 (2.32; 4.06) 0.01
 After 4.19 (3.20; 5.75) 3.26 (2.28;4.42) 0.03
hsCRP (mg/L)
 Before 1.71 (0.72; 3.10) 1.52 (0.76; 2.53) 0.73
 After 1.97 (0.98; 3.13) 1.75 (0.66; 3.73) 0.67
IL‑6 (pg/mL)
 Before 2.03 (1.49; 3.32) 1.97 (1.57;2.38) 0.66
 After 1.95 (1.19; 3.76) 2.05 (1.69; 3.43) 0.50
TNF‑α (pg/mL)
 Before 1.48 (1.29; 1.72) 1.51 (1.26; 1.84) 0.66
 After 1.47 (1.25; 1.86) 1.46 (1.21; 1.76) 0.73
sICAM‑1/CD54 (ng/mL)
 Before 205.87 (169.4;258.7) 222.64 (168.2; 241.2) 0.94
 After 201.88 (168.0; 262.4) 208.27 (178.3; 271.6) 0.74
sVCAM‑1/CD106 (ng/mL)
 Before 875.20 (659.8; 1385.0) 1138.2 (818.6; 1604.3) 0.11
 After 832.95 (638.3; 1515.0) 1275.3 (825.9; 1554.9) 0.06
Myeloperoxidase (ng/mL)
 Before 28.80 (18.43; 40.68) 40.46 (20.16; 55.57) 0.15
 After 28.24 (18.56; 44.92) 29.18 (24.21; 48.99) 0.60
RvD1 (pg/mL)
 Before 244.60 (150.1; 457.5) 237.40 (123.40; 469.0) 0.59
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similar in both groups. Two patients (from both groups 
each) withdrew from the study during the run-in period 
because of noncompliance to the study protocol due to 
diarrhea (n = 1) and nausea (n = 1). There were no major 
cardiac adverse events (MACEs) during the follow-up in 
either of the groups.
Discussion
Our study demonstrated that a 3-month treatment with 
a higher dose of n-3 PUFAs (1 g of EPA and 1 g of DHA 
acids), added to OMT in patients with CVD and with 
long-standing and well-controlled DM2 did not affect 
platelets aggregation and coagulation, when measured 
by specified tests, which were used. Moreover, it did not 
influence inflammatory or metabolic status. This is the 
first study that attempted to elucidate, in a comprehen-
sive manner, the various mechanisms responsible for 
the effect (or lack of it) of treatment with n-3 PUFAs in 
patients with atherosclerosis and DM2. The ORIGIN 
(Outcome Reduction With Initial Glargine Intervention) 
study demonstrated no effect of a lower dose of PUFAs 
(1 g daily) on HbA1c levels or MACE and all-cause mor-
tality in patients with DM2 and prediabetes [2]. However, 
recently, Kwong et al. [3] have shown that 4 g of PUFAs 
daily were associated with reduction of adverse left 
ventricular remodelling, non-infarct myocardial fibro-
sis, and serum biomarkers of systemic inflammation, in 
patients with acute myocardial infarction, on guidelines-
based therapies. The discrepancies in the effectiveness 
of treatment with a higher dose of n-3 PUFAs between 
the studies may be explained by the differences in study 
populations and protocols. In the study by Kwong et al. 
[3], acute myocardial infarction was present in about 
45% of the patients, while in our study, stable CAD and/
or peripheral artery disease and DM2 was diagnosed in 
all patients. The procoagulant state related to DM2 may 
be so potent that it cannot be attenuate or abolish by the 
subtle effects of n-3 PUFAs, which most likely are pre-
sent in diabetic patients. Moreover, the higher dosage 
of n-3 PUFAs, 4 g for 6 months used by Kwong et al. [3] 
versus 2 g for 3 months in our study, might have affected 
the results. In our study, no significant differences were 
found in platelet aggregation and fibrin clot properties 
between the n-3 PUFA and placebo groups during the 
3  months of treatment. Although, we noticed a signifi-
cant intergroup difference in F1.2 levels at the end of the 
study. This marker of in vivo thrombin generation might 
suggest that in the placebo group thrombin formation is 
more prone to enhancement with time, while the ther-
apy attenuates such effect. It remains to be established 
whether this phenomenon is mediated by increased TF 
expression in high risk CV patients. However, we can-
not exclude that this was an artifact probably caused by a 
limited study population.
The beneficial effect of n-3 PUFAs on the blood coagu-
lation has been observed in health and disease states in 
numerous small-scale clinical studies [15]. Supplementa-
tion of 1 g/day of n-3 PUFAs for 1 month has been shown 
to exert antithrombotic effects and potentiate platelet 
response to clopidogrel in patients with stable CAD, 
who underwent percutaneous coronary intervention [13, 
16]. One month of 1 g of n-3 PUFAs daily has also been 
found to alleviate the hypercoagulable state by decreas-
ing thrombin formation and improving plasma fibrin clot 
properties in those patients [14]. Such effects were not 
observed in patients with DM2 as reported in the present 
study.
Data concerning the effects of n-3 PUFAs on the coag-
ulation profile in diabetic patients are scarce and incon-
sistent. In contrast to our results, a reduction in platelet 
aggregation was observed after 8 weeks of treatment with 
either 1800 or 900 mg of EPA daily in patients with non-
insulin-dependent diabetes without CVD [17]. In another 
study, 3 g of n-3 PUFA given for 8 weeks in noninsulin-
dependent diabetes increased plasminogen activator 
inhibitor-1 levels, resulting in the impairment of fibrino-
lytic capacity [18]. However, the limitations of the above 
study was a small study population (14 patients) and the 
use of placebo made from olive oil, which is a rich source 
of biologically active monounsaturated fatty acids.
Discrepant results of the studies might also be 
explained by the fact that in the current study, we placed 
a special emphasis on optimization of therapy and most 
of our participants underwent intensification of lipid 
control, mainly by increasing statin doses, before enroll-
ment. It has been shown that statins improve a procoag-
ulant status in DM2 [19]. In our study, the mean doses 
of atorvastatin, rosuvastatin, and simvastatin were 30.5, 
16.5 and 22.9  mg, respectively. Thus, it is possible that 
the anticoagulant properties of statins might have over-
whelmed the effects of n-3 PUFAs. Moreover, high fast-
ing TG levels were shown to predict the potential of 
n-3 PUFAs to decrease the levels of several coagulation 
Table 3 continued
Variables Placebo
N = 38
n‑3 PUFAs
N = 36
p value
 After 232.85 (144.65; 409.4) 184.90 (106.08; 660.6) 0.74
Data shown as number (percentage) for categorical variables and mean 
(±standard deviation) or median (IQR) for continuous variables
HbA1c glycated hemoglobin, TC total cholesterol, LDL-C low-density lipoprotein 
cholesterol, HDL-C high-density lipoprotein cholesterol, TG triglycerides, hsCRP 
high-sensitivity C-reactive protein, IL-6 interleukin-6, TNF-α tumor necrosis 
factor-α, ICAM-1 intercellular adhesion molecule-1, VCAM-1 vascular adhesion 
molecule-1, RvD1 resolvin D1
* p = 0.01 within the placebo group
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Fig. 2 Permeation coefficient (Ks), before (a) and after intervention (b); endogenous thrombin potential (ETP), before (c) and after intervention (d); 
platelet aggregation—5 mmol/L of arachidonic acid (PR AA) before (e) and after intervention (f) in placebo and n‑3 PUFAs group. Horizontal line 
median; upper and lower margin of rectangle interquartile range, vertical line observation away from 1.5 quartiles
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factors (V, VII, and X) and reduce thrombin generation 
[20]. Since the mean TG concentration in our patients 
was low (1.35 mmol/L) owing to intensive lipid control, 
it might have also limited the effect of n-3 PUFAs on the 
coagulation status.
Our results suggest that the higher dose of n-3 PUFAs 
in optimally treated patients with DM2 and CVD does 
not improve the metabolic status, including lipid control, 
insulin sensitivity, and adipokine profile. However, we 
may hypothesize that due to a high degree of metabolic 
dysregulation in obesity and DM2, a 3-month treatment 
with 2  g of n-3 PUFAs might not be potent enough to 
improve the endocrine activity of fat tissue. Moreover, 
the high effectiveness of modern OMT may limit the ben-
eficial effects of n-3 PUFAs. Therefore, it is possible that 
higher doses and longer therapy with n-3 PUFAs would 
have improved the metabolic status in DM2. On the other 
hand, due to “metabolic memory” observed in DM2, sub-
optimal glucose control in the early stages of DM2, espe-
cially long-term disturbances in the glucose profile, might 
explain the lack of metabolic benefits of n-3 PUFA sup-
plementation, even after the intensification of treatment.
The available RCTs investigating the effect of n-3 
PUFAs on glucose metabolism showed inconsistent find-
ings, demonstrating mainly neutral or slightly beneficial 
effects. Several studies suggested the usefulness of n-3 
PUFAs in DM2 prevention [21–23]. Nevertheless, the 
effect of n-3 PUFAs in those studies might have been 
stronger due to the lack of DM2 and lower degree of met-
abolic disturbances as compared to our study.
A recent study by Sawada et  al. [24] in patients with 
newly-diagnosed impaired glucose metabolism, includ-
ing both diabetes and impaired glucose tolerance (IGT), 
accompanied by CAD, has shown favorable effects of 
1800  mg of EPA daily on postprandial hyperglycemia, 
hyperlipidemia, and insulin secretion. However, no 
changes were noticed in fasting immune reactive insulin 
or HbA1c levels. Compared to our study, it was an open-
label, single-blind study, where only EPA without DHA 
was supplemented. There were also differences in study 
population: patients with CAD and newly diagnosed 
diabetes or IGT in the study by Sawada et al. [24] versus 
patients with CVD and long-standing DM2 in our study. 
Thus, higher impairment of the metabolic status in our 
study population may be assumed. Sarboluki et  al. [25] 
demonstrated that a 3-month treatment with 2 g of EPA 
in overweight Asian patients with DM2 improved glu-
cose control indices such as insulin, fasting plasma glu-
cose (FPG), HbA1c, and homeostasis model assessment 
of insulin resistance (HOMA-IR). However, compared 
to our study, their population was younger, with a higher 
percentage of women, lower mean body mass index, 
shorter duration of DM2, and without insulin treatment. 
On the other hand, a recent meta-analysis by Chen 
et  al. [26] demonstrated that in DM2 n-3 PUFAs did 
not change HbA1c, fasting insulin, FPG, or postprandial 
glucose levels, which is in accordance with our results. 
Nonetheless, most RCTs included in the meta-analysis 
were carried out within a period of 3 months, and it may 
be speculated that longer supplementation might have 
improved glycemic control.
Also a few trials evaluating higher doses of n-3 PUFAs 
(4 g/day of n-3 PUFAs and 3–18 g/day of fish oil) than the 
dose used in our study (2 g) supported our findings of no 
effect of n-3 PUFAs on glucose metabolism in DM2 [27, 
28].
Regarding n-3 PUFA-mediated effects on adiponectin 
and leptin levels in patients with DM2, our observations 
are in agreement with the studies by Striban et  al. [29], 
where 2  g daily of EPA/DHA were administered, and 
Kabir et al. [30], where patients received 1.8 g/day of n-3 
PUFAs. A recent meta-analysis demonstrated that n-3 
PUFA therapy is mildly associated with decreased plasma 
leptin levels only in nonobese participants [31], which 
is in line with our results. Although n-3 PUFAs might 
moderately increase adiponectin levels [32], the only 
study performed in patients with DM2 demonstrated no 
impact of n-3 PUFAs on adiponectin levels.
In the present study, after treatment with a high dose 
of n-3 PUFAs, EPA and DHA concentrations were very 
high with no change in RvD1 levels. During the study, 
n-3 PUFAs exerted no significant effect on inflammatory 
markers such as hsCRP, IL-6, TNF-α, ICAM-1, VCAM-
1, or myeloperoxidase. We hypothesize that the lack of 
the anti-inflammatory properties of n-3 PUFAs in DM2 
may result from impaired synthesis of their active metab-
olites associated with long-term advanced DM2 and 
atherosclerosis.
Our study has several limitations. First, the duration 
of treatment was relatively short and the sample size was 
limited. However, our previous studies showed that the 
benefits of n-3 PUFA supplementation can be seen in a 
1-month observation. Second, we did not assess clinical 
endpoint. A certain impact of potential confounders such 
as diet, physical activity, or cigarette smoking cannot be 
excluded.
Conclusions
In conclusion, our study demonstrated that in patients 
with long-standing, well-controlled DM2 and atheroscle-
rotic disease the treatment with a high dose of n-3 PUFAs 
(namely, 1 g/day of EPA and 1 g/day of DHA for 3 months) 
does not improve coagulation, metabolic, and inflamma-
tory status when measured with the specified tests. Fur-
ther studies are needed to clarify a role of n-3 PUFAs in 
the regulation of complex processes active in vivo.
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